To determine the effectiveness of a 10-day subcutaneous erythropoietin (rHuEpo) course of 300 units per kg per dose plus oral iron compared to oral iron alone in anemic infants during their convalescent phase of illness.
INTRODUCTION
Low birth weight newborns, <1500 g, are at risk of developing severe and prolonged drops in hematocrit concentrations after birth, resulting in the need for red blood cell (RBC) transfusions. This fall in hematocrit is multifactorial and includes the premature infant's attenuated response to tissue hypoxia, low levels of circulating erythropoietin, reduced life span of fetal red cells and iatrogenic phlebotomy loss that occurs as a result of their medical condition. The progressive decline in hematocrit in these infants is termed ''anemia of prematurity''. Symptoms associated with anemia of prematurity include tachycardia, tachypnea, poor weight gain, periodic breathing and acidosis. Provision of packed RBC transfusions and/or use of recombinant human erythropoietin alfa (a stimulator of red cell production) are often used to treat or attenuate anemia.
Transfusions have the complications of blood-borne infections, hyperkalemia, graft-versus-host disease and further suppression of the bone marrow erythroid lineage. Recombinant human erythropoietin therapy (rHuEpo) carries less risk, but the success of this therapy has varied. With the advent of conservative RBC transfusion guidelines in premature infants, the utility of rHuEpo may be even more challenged. However, on balance, it has been possible to show stimulation of erythropoiesis and a modest decrease in the number of transfusions administered. [1] [2] [3] [4] [5] [6] [7] [8] Variability in therapy success has stemmed from the wide range of studied dosage regimens (75 to 1500 U/kg/week) as well as other factors including age at onset of therapy and dose of supplemental iron therapy.
Prior to the initiation of this investigation, we observed that despite our best efforts to eliminate the need for RBC transfusions, there remained a population of infants who, during their convalescent phase of illness, became anemic and developed late symptomatic anemia that required treatment. In an effort to stimulate these infants to produce more RBC, we empirically provided short-term rHuEpo therapy (300 U/kg/day subcutaneously for 7 to 10 days). It was our observation that most of these infants responded well to this course and avoided the need for a late red cell transfusion. However, this regimen had not been studied in a prospective, scientific manner. Therefore, the rationale for this investigation was to evaluate the effectiveness of a short course of erythropoietin in infants during the convalescent phase of illness. We hypothesized that this 10-day regimen would increase hematocrit and reticulocyte count post-treatment, and reduce the risk for a late RBC transfusion.
MATERIALS AND METHODS Patient Eligibility
Infants were eligible for study inclusion if their gestational age at birth was less than 32 weeks, hematocrit was less than or equal to 28% with a corrected reticulocyte count of less than or equal to 5%, they were less than 48 weeks postconceptual age or 5 months chronological age, and had a diagnosis of anemia of prematurity. Infants were ineligible if they had a pathologic cause for anemia such as decreased red cell production/bone marrow failure secondary to hypothyroidism, Blackfan-Diamond anemia, Fanconi's anemia or parvovirus; if they had shortened red cell survival secondary to isoimmune-mediated hemolysis, acute intercurrent infection, congenital red cell membrane disorders (heriditary spherocytosis), congenital red cell enzyme disorders (G6PD deficiency, pyruvate kinase deficiency), congenital hemoglobinopathies (thalassemias) or metabolic errors (galactosemia, organic aciduria)); if they had an acute intercurrent illness or if they had a continued phlebotomy loss of greater than 5% of body weight per week.
Prior to consideration for study enrollment, there was no effort made by the investigators to control for RBC transfusions or rHuEpo use. Conservative transfusion guidelines were in place and followed. Criteria for RBC transfusion in the acutely ill infant requiring mechanical ventilation or nasal continuous positive airway pressure included: phlebotomy loss of greater than 15% of blood volume associated with hypotension, or hematocrit less than 30%. Criteria for RBC transfusion in the convalescent infant requiring no more than supplemental oxygen included: hematocrit less than 28% with symptomatic anemia (tachycardia, poor somatic growth or metabolic acidosis) or hematocrit less than 20%. Infants meeting inclusion criteria were enrolled into the study after obtaining informed consent from a parent or guardian. This protocol was reviewed and approved by the Colorado Multiple Institution Review Board and the General Clinical Research Program National Centers for Research Resources NIH.
Study Design
This was a prospective, randomized, controlled trial where infants were randomized into one of two groups. Group A received subcutaneous rHuEpo (Epogen alpha (2000 U/ml), Amgen Inc., Thousand Oaks, CA) at 300 U per kg per dose every day for 10 days with supplemental oral elemental iron at 4 mg per kg per day in two divided doses. Group B received only supplemental oral elemental iron at 4 mg per kg per day in two divided doses. Since all infants were receiving full enteral feedings with iron, a total of 6 mg per kg per day of enteral iron was provided to both groups. A clinical research nurse assigned infants to a study group using a random number table. Erythropoietin and iron were administered by neonatal staff nurses. All study drugs were prepared and dispensed by the University of Colorado, Department of Pharmacy. At the end of the 10-day treatment period, the treatment protocol was concluded and further management of anemia was at the discretion of the attending neonatologist.
The following clinical and objective markers associated with anemia of prematurity were collected and compared between groups: baseline hematocrit and corrected reticulocyte count, posttreatment hematocrit and corrected reticulocyte count, bradycardia events (qualified as self-resolving, mild, moderate or severe), somatic growth (grams/day), supplemental dose (units per kg) of rHuEpo required after the 10-day treatment period, number of red cell transfusions required after study enrollment and hematocrit and corrected reticulocyte count at term equivalent age. Infants were followed from the time they were enrolled into the study until they were discharged from the hospital. At six months of age, these infants were evaluated again for hematocrit and corrected reticulocyte count as a safety assessment to be sure that there were no negative effects of this treatment regimen. The 6-month evaluation took place at The Children's Hospital outpatient clinic, under the supervision of one of the investigators (AR).
Statistical Analyses
The primary outcome of the proposed study was to test the null hypothesis that the two study group hematocrit means were equal at the end of the treatment period. Sample size was estimated using a two-tailed type I error (alpha) of 0.05 and a power of 80%. The statistical software program SamplePower (SPSS, Inc., Chicago, IL) calculated a sample size of 25 per group. This computation assumed a mean difference of 3.3 (corresponding to hematocrit means of 33.0 versus 29.7, or a 10% difference) and a common within-group standard deviation of 4. This effect was selected as the smallest effect that would be important to detect, in the sense that any smaller effect would not be of clinical significance. It was also assumed that this effect size was reasonable, in the sense that an effect of this magnitude could be anticipated in this field of research. To compensate for expected patient drop-out in the follow-up phase of this study, we enrolled an additional 20% (or five additional patients per group) for a total of 30 patients into each group.
Distributions of the values of hematocrit and corrected reticulocyte counts at each time point were analyzed for normality, skewness and kurtosis. The independent sample t-test was used to test the hypothesis that the two study group means were equal. Secondary comparisons were made regarding (1) bradycardia events, (2) growth, (3) amount of poststudy supplemental rHuEpo required and (4) number and volume of red cell transfusions required. Since the risk of infection is theoretically linked to the number of donor exposures, we estimated that a reduction of one transfusion per patient was deemed clinically relevant. This target RBC reduction seemed particularly justified because infants that met inclusion criteria for this study were beyond their acute illness and hence past their high RBC requirement. These secondary outcomes were analyzed by the t-test if normally distributed. When data distributions were found to be significantly different from the normal distribution, appropriate nonparametric methods (Mann-Whitney U rank sum test) were applied. Since the protocol was relaxed after the initial 10-day treatment period and infants were allowed to cross over and receive supplemental rHuEpo, we performed a Fisher's exact test to detect any difference in the percent of subjects who received additional rHuEpo during this open protocol period.
RESULTS

Patient Characteristics
Baseline characteristics of the study groups are shown in Table 1 . A total of 60 infants were enrolled into the study (n ¼ 30 per group). Three infants were withdrawn from initial data analysis (n ¼ 1 from Group A and n ¼ 2 from Group B) because posttreatment laboratory variables were not obtained, leaving a total of 57 infants. Five infants from Group A and four infants from Group B were lost to follow-up at the 6-month corrected age evaluation, leaving a total of 24 patients per group available for analysis at 6 months. There were no significant differences between the groups at the time of enrollment with regard to baseline characteristics. Seven infants in Group A and five in Group B received rHuEpo for treatment of anemia prior to study entry. No infant was receiving rHuEpo at the time of study enrollment.
Effect on Hematopoiesis
Infants randomized to Group A had a significantly higher posttreatment hematocrit and corrected reticulocyte count than infants in Group B (Figure 1a and b) . There was no difference at term equivalent (40 weeks postconceptual age) and at 6 months corrected age. However, 32% of infants who were initially randomized to the no rHuEpo group (Group B) did, in fact, receive rHuEpo after the 10-day treatment period, compared to only 6.9% in Group A (p ¼ 0.01).
Change in Secondary Outcomes
During the treatment period, all infants showed appropriate growth with adequate caloric intake. The average weight gain was 28±8 g Figure 1. (a) The effect of study group on mean serum hematocrit (mg/dl). Group A (erythropoietin 300 U/kg/day Â 10 days þ iron) and Group B (iron alone). Serum hematocrit was significantly different at post-treatment (*p<0.001). (b), The effect of study group on mean corrected reticulocyte count (%). Group A (erythropoietin 300 U/kg/ day Â 10 days þ iron) and Group B (iron alone). Corrected reticulocyte was significantly different at post-treatment (*p<0.05).
per day and 32±8 g per day and the average number of kcals per kg was 125±8 and 123±9 in Groups A and B, respectively (p ¼ 0.13 and 0.42). All infants experienced some type of bradycardia events, but the number and quality of these events was not statistically different between the groups ( Table 2 ). The total number of units per kg of subsequent rHuEpo required from Groups A and B was 260±1014 and 841±1250 per patient, respectively (p ¼ 0.014).
Effect on RBC Transfusion Requirements
After enrollment into the study, a total of two transfusions were required from Group A F both transfusions were provided to the same infant. A total of eight transfusions were required for Group B, with one patient requiring six transfusions. The infant who required six transfusions was the youngest infant enrolled into the study with an enrollment weight of 860 g and a postconceptual age of 29 weeks. When expressed as a percentage of patients requiring a transfusion, 3.4% of patients in Group A and 10.7% of patients in Group B required a transfusion. In terms of volume of RBC required, Group A required 1±5 cm 3 per kg and Group B required 3.1±14 cm 3 per kg (p ¼ 0.47). In an effort to determine if the additional rHuEpo received in the open protocol period had an impact on the risk of transfusion, we performed a logistic regression analysis and found a 28% risk reduction in the need for an RBC transfusion in those subjects who received additional rHuEpo (p ¼ 0.30).
SIGNIFICANCE
This is the first study to publish the effect of a short course of daily rHuEpo on hematocrit and reticulocyte counts in infants during their recovery phase of illness. In this study, we compared the efficacy of a 10-day subcutaneous rHuEpo course (plus oral iron therapy) to oral iron therapy alone. The results of this investigation indicate that a short course of subcutaneous rHuEpo therapy resulted in a significant increase in post-treatment hematocrit and reticulocyte count. There was a trend toward a reduction in the risk of an RBC transfusion based on initial study group designation, but this reduction was not statistically significant. It is possible that the lack of RBC risk reduction was attributable to the fact that a statistically significant larger proportion of infants randomized to Group B (iron alone) received subsequent rHuEpo therapy after the 10-day treatment period and before discharge than Group A (32 versus 6.9%). This additional rHuEpo administration provided to infants originally randomized to iron only (Group B) pushed the original study groups toward equality after the 10-day treatment period. This bias toward equivalence makes any conclusion about the effect of this rHuEpo regimen on RBC use difficult, but does not diminish the acute effects seen.
Anemia of prematurity is a relatively common problem within the neonatal intensive care unit. Current strategies to treat this anemia include the provision of red cells through transfusions and/or the use of rHuEpo to stimulate hematopoiesis. Despite improved screening of RBC donors, there continue to be infectious risks associated with liberal RBC transfusions, including transmission of hepatitis, variant Creutzfeldt-Jakob disease and West Nile virus. 9, 10 Noninfectious risks of RBC transfusions include hyperkalemia, graft-versus-host disease and further suppression of the bone marrow erythroid lineage. Consequently, there has been a strong movement within the neonatal practice environment to develop more stringent transfusion guidelines. These guidelines, along with a concerted effort to reduce phlebotomy loss, have substantially reduced transfusion requirements. To further reduce RBC transfusions, the administration of rHuEpo has been studied in a variety of settings. Not all dosing schemas and rHuEpo strategies have proven successful. Even prolonged courses of rHuEpo provided to infants as early as 96 hours of life and continued until 35 weeks gestation have met with mixed results.
11
Prior to the initiation of this investigation, we performed a retrospective analysis to determine which factors (patient and/or drug regimen) correlated with rHuEpo therapy success in our center. 12 We established that (a) prompt initiation of therapy (within the first week of life) improved mean hematocrit; (b) advanced postconceptional age (>34 weeks PCA) at therapy discontinuation reduced number of transfusions, and (c) mean rHuEpo and iron doses correlated with higher mean corrected reticuloctye counts. While this information was helpful to our practice, we felt that routine provision of prolonged rHuEpo courses to all ''at-risk'' infants would result in excessive use of this hematopoietic agent. The reduction of ''early'' RBC transfusions in the critically ill infant is difficult to achieve with rHuEpo. In addition, these early transfusions can often be given from a single 8 using weighted regression analysis found that the number of late transfusions per patient was a function of rHuEpo dose and that for every 500 U per kg per week increase in rHuEpo dose, the average number of late transfusions required per patient decreased by approximately 3/4 of a transfusion. Therefore, it should not be surprising that the rHuEpo regimen studied here resulted in positive effects on erythropoiesis and a trend toward second-donor RBC risk reduction. The advantage of our proposed rHuEpo regimen over other regimens studied is that it can effectively raise hematocrit and reticulocyte counts in a compressed period of time. In addition, discomfort associated with repeated injections can now be reduced with the use of an Insuflon s catheter (Chronimed/ Hypogard). This Insuflon s catheter is a unique plastic catheter system designed to deliver very small volumes of drugs into the subcutaneous tissue. Originally studied for the delivery of insulin, this device can be inserted via a needle and remain in place for up to 7 days F mitigating the need for multiple daily subcutaneous injections of rHuEpo required with the rHuEpo regimen described in this paper.
CONCLUSION
Short-term, subcutaneous rHuEpo therapy at 300 U per kg per dose for 10 days is associated with an acute improvement in hematocrit and corrected reticulocyte counts in anemic premature infants during their convalescent phase of illness, when expected phlebotomy loss remains less then 5% of body weight per week. It remains unclear if this regimen provides significant second-donor RBC risk reduction. However, this approach could replace longterm rHuEpo administration aimed at preventing late anemia. The results of this investigation demonstrate the effectiveness of a short course of erythropoietin.
